MS1819: Ph IIa started

AzurRx began an open-label, dose-escalation, Australian and New Zealand Phase IIa trial to evaluate 280, 560, 1,120 and 2,240 mg doses of MS1819 daily for 48-60 days in about 12 patients. Under an ame...